ZAFA Pharmaceutical faces several challenges in Pakistan's political, economic, social, and technological environment:
Politically, price pressures and supply issues due to strikes increase costs and hurt availability. Economically, high taxes, duties, and inflation make it difficult to determine pricing and introduce new drugs. Socially, diseases are growing rapidly but poverty prevents affordable access to needed medications. Technologically, innovation is restricted by regulations and litigation while infrastructure investment is hindered by the economic climate and power outages.
Growth drivers in Indian Pharma Industry pharmacampus
Indian pharma industry growth is driven by Supply Side Drivers, demand-side drivers, and government policy support.
References:
https://www.ibef.org/industry/pharmaceutical-india.aspx
Growth drivers in Indian Pharma Industry pharmacampus
Indian pharma industry growth is driven by Supply Side Drivers, demand-side drivers, and government policy support.
References:
https://www.ibef.org/industry/pharmaceutical-india.aspx
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
Key Developments Propelling The Pharmaceutical IndustrySteven Scansaroli
Advancements in technology in the last few decades have led to revolutionary innovations in the pharmaceutical industry and healthcare in general. https://sites.google.com/site/stevenscansarolius/blog/key-developments-propelling-the-pharmaceutical-industry
R&D less innovative but increasingly costly
Manufacturing is less sustainable in the West - shift to developing
markets
Health care costs rising globally – pressure on prices/profits
Emergence of non-communicable diseases (NCD’s)
Demand for medicines is growing more rapidly in the emerging
economies than the industrialized economies
Push towards generics over patented medicines
Focus on access to quality healthcare in Africa
Improving manufacturing/quality standards in developing countries
Increasing political support for local manufacturing in Africa
Greater focus on Africa as a “Market Opportunity
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
Key Developments Propelling The Pharmaceutical IndustrySteven Scansaroli
Advancements in technology in the last few decades have led to revolutionary innovations in the pharmaceutical industry and healthcare in general. https://sites.google.com/site/stevenscansarolius/blog/key-developments-propelling-the-pharmaceutical-industry
R&D less innovative but increasingly costly
Manufacturing is less sustainable in the West - shift to developing
markets
Health care costs rising globally – pressure on prices/profits
Emergence of non-communicable diseases (NCD’s)
Demand for medicines is growing more rapidly in the emerging
economies than the industrialized economies
Push towards generics over patented medicines
Focus on access to quality healthcare in Africa
Improving manufacturing/quality standards in developing countries
Increasing political support for local manufacturing in Africa
Greater focus on Africa as a “Market Opportunity
How is drug spending affected in the year 2017Steve Martin
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
An introduction to Myanmar's current healthcare system with an eye on whether the country is ready for meaningful foreign direct investment in the sector.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
IIBMS ANSWER SHEETS
IIBMS MBA CASE STUDY ANSWER SHEETS -
IIBMS MBA CASE STUDY SOLUTIONS -
IIBMS EMBA CASE STUDY ANSWER SHEETS -
IIBMS EMBA CASE STUDY SOLUTIONS -
IIBMS DMS CASE STUDY ANSWER SHEETS -
IIBMS DMS CASE STUDY SOLUTIONS -
IIBMS MMS CASE STUDY ANSWER SHEETS -
IIBMS MIB CASE STUDY SOLUTIONS -
MBA IIBMS ANSWER SHEETS -
EMBA IIBMS CASE STUDY SOLUTIONS -
ACADEMIC WRITING SERVICES -
Global Study Solutions -
Dr. Aravind Banakar -
aravind.banakar@gmail.com -
www.mbacasestudyanswers.com -
9901366442 – 9902787224
Searches related to Leadership report
project report on leadership styles
project report on leadership pdf
democratic leadership report
leadership essay
i opt leadership styles
internship report on leadership
report writing
leadership styles pdf
social behaviour in animals
social behaviour pdf
social behaviour ppt
social behaviour synonym
social behavior definition biology
three levels of social behavior
essay on social behaviour
understanding social behaviour
Searches related to Lessons From UP Movie
purpose of the movie up
3 lessons from up movie 2009
up movie lesson plans
what does the movie up teach us
up movie message
what is the central theme of the movie up
up film study
how does the movie up end
islamic car loan
best car ijarah in pakistan
meezan bank car financing calculator
meezan bank loan
car on lease
soneri bank car finance calculator
bop car loan calculator
islamic bank car loan
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
2. Political:
The most common problem a pharmaceutical company faces is the Price Pressure
that rustled in increasing prices of “Medical Drugs” which somehow creates an
inflationary impact on our society and on our organizing as well. Due to the strikes
in our city (Karachi) mostof the organizational work stuck which puts ZAFA in to a
dire situation While, Customer wants Medical Drugs at low costs which becomes
impossibleto them.
On the other hand, ZAFA faces a problem of Raw Material supply on time because
of uncertain conditions which we faces every day in Karachimakes their way to
producemore Drugs cutin manufacturing in huge amountwhich somehow
creating rigidity in availability in drug availability all over the Pakistan and outside
of Pakistan.
Economic:
Now a days, Pakistan is facing a huge amountof inflation where Taxes are high.
Excise Duty (State & Central), Custom Duty, ServiceTax, Profession Tax, License
Fees, Royalty, Pollution Clearance Tax, Hazardous substance(Storage& Handling)
license, income tax, Stamp Duty and a host of other levies and charges have to be
paid. On an average it amounts to no less than 40-45% of the costs. So, it’s really
hard to determine that whether, Tomorrow, ZAFA uses the samepolicies rules
and regulations or not.
ZAFA want to work on latest DRUGS which haven’tintroduced in Pakistan but
unfortunately there are some economic factors which are lacking as described
above that makes a huge hindrance in the path or learning and growing up in
ZAFA. Economic factors affects a lot on an organization but when it comes to
pharmacy it needs innovation every day and economy should be growing to
producehuge amount of less cost drugs for facilitating every single person living
in our society.
3. Social:
There is also the problem of the increasing obesity amongstthe population and its
associated health risks. Now a days, Poverty is the biggestproblem we are facing
and the high cost drugs arekilling them and ZAFA cannot cut their prices just
because of the Economic and Political factors they are facing. Moreover, The
growing diseases wehave in our society which are gowning so fastare TB, Dengue
and Heart Attack which needs high medication which can be fulfilled by huge
amount of money. Patients and home careers are becoming moreinformed. Their
expectations have changed and they have become more demanding. Fulfilling
their demand is the firstjob for them.
The drugs needed them to produceneeded high amount of raw material and
economic stability to cut down their prices so that it can be provided to every
single person living in our society.
Technological:
Innovation is the first step on the stars of success. Industry has many regulatory
and legislative restrictions. There is also a growing cultureof litigation in many
countries. The evolution of the internet is also stretching the legislative
boundaries with patient’s demanding more rights in their healthcare
programmers’. ZAFA has to upgradetheir bio-tech infrastructureby investing in
bio technological structurebut no one wants to invest becauseof recession and
inflation.
While, Other competitors which mostly European are getting it very easily but in
Pakistan ZAFA faces a huge problemin investing in technology and the other
factor we face here is load shedding which makes technological factor nothing but
a piece of iron. So, not justinvesting but electricity failure in technological part.